PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.79%
Both yoy net incomes decline, with AVXL at -103.32%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-4.72%
Negative yoy D&A while AVXL is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.68%
Both cut yoy SBC, with AVXL at -11.09%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
284.52%
Well above AVXL's 127.09% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
299.08%
AP growth of 299.08% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-348.88%
Negative yoy usage while AVXL is 127.09%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
208.62%
Well above AVXL's 299.12%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
35.18%
Some CFO growth while AVXL is negative at -94.10%. John Neff would note a short-term liquidity lead over the competitor.
82.00%
CapEx growth of 82.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.00%
We expand invests by 82.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.